** U.S.-listed shares of drugmaker climb 2.5 pct to $25.81 premarket
** BHC posts Q4 rev of $2.12 bln and adj EBITDA $858 mln above analysts’ estimates; Also forecasts better-than-expected 2019 rev and adj EBITDA
** Brokerage Stifel says results and forecast show the “first demonstration of potential growth since 2015”
** Co expects 2019 rev of $8.3 bln-$8.5 bln and adj EBITDA of $3.35 bln-$3.50 bln; Mizuho analyst says forecast includes upside from recently acquired products like Trulance
** Stock up 36 pct so far this year (Reporting by Saumya Sibi Joseph in Bengaluru)
Our Standards: The Thomson Reuters Trust Principles.